Laura Dempsey

Ms. Laura Dempsey


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BABenjamin Atkin
Benjamin Atkin
Thozhukat  Sathyapalan Thozhukat Sathyapalan
Thozhukat Sathyapalan
LDLaura Dempsey
Laura Dempsey
SAStephen L Atkin
Stephen L Atkin
ABAlexandra E. Butler
Alexandra E. Butler
Type 2 diabetes (T2D) is associated with normal or higher bone mineral density (BMD), but there is a higher fracture rate. Hypoglycaemia does not affect BMD but may cause fractures directly through falls and may affect bone cellular metabolism. We examined circulating bone marker proteins (BMPs) in response to induced hypoglycaemia in T2D versus controls. A prospective exploratory parallel study design was conducted in T2D patients (n = 23) and healthy controls (n = 23) who underwent blood SOMAscan proteomic analysis of bone biomarkers at baseline, hypoglycaemia, and post-hypoglycaemia time points. Unadjusted repeated measures linear mixed modeling was used for analysis. Linear mixed modeling of the proteins showed that the way most BMPs changed over time did not differ between groups. At baseline, Dickkopf-related protein 1 (DKK1), cathepsin A, cathepsin S, and cathepsin Z were increased in T2D versus controls (p < 0.05), whilst fibroblast growth factor 23 (FGF23) was lower in T2D versus controls (p ≤ 0.05). Following hypoglycemia, transient changes from baseline occurred in DKK1, cathepsin A, cathepsin G, cathepsin H, cathepsin S, cathepsin Z, parathyroid hormone (PTH), Sphingosine kinase 1 and 2 (SPK1/2), and interleukin-1 beta (IL1 beta) over the post-hypoglycaemia time course. There was decreased cathepsin S in T2D from baseline to 24 h compared to the control group, and increased cathepsin Z at 24 h for both groups overall compared to baseline (p < 0.05). Baseline-raised cathepsins (A, S, Z) in T2D may enhance osteoclastic resorption, whilst raised DKK1 could inhibit osteoblast differentiation and suppress bone formation. Hypothetically, this may lead to a decline in bone quality through a resorption-enhanced, low bone formation imbalance. The effects of hypoglycaemia on bone physiology appear to extend significantly beyond the initial insult, as seen for cathepsin S and Z, which differed at 24 h compared to baseline.

Verified
Journal Article
Open access
PDF file
RDRadwan Darwish
Radwan Darwish
Thozhukat  Sathyapalan Thozhukat Sathyapalan
Thozhukat Sathyapalan
LDLaura Dempsey
Laura Dempsey
MAMohammed Abdalla
Mohammed Abdalla
ABAlexandra E. Butler
Alexandra E. Butler
SAStephen L Atkin
Stephen L Atkin
Women with polyendocrine metabolic ovarian syndrome (PMOS) have heterogeneous metabolic risk. We investigated whether targeted circulating proteins were associated with incident type 2 diabetes (T2D) and whether the retained proteins responded to experimentally induced lipid stress. In Cohort 1, 231 women with (n = 135) or without (n = 96) PMOS had T2D outcome data, of whom 25 developed T2D during a median follow-up of 12.7 years (range 10.2–15.1); 221 women (20 incident cases) had complete covariate data for adjusted analyses. Of 44 available proteins, 27 were prespecified from prior literature; following Benjamini–Hochberg adjustment, eight biomarkers (Adiponectin (ADIPOQ), Endocan (ESM1), Mast/stem cell growth factor receptor-Kit (KIT), Chordin Like 1 (CHRDL1), Cell Adhesion Molecule L1 Like (CHL1), Cathepsin V (CTSV), L1 Cell Adhesion Molecule (L1CAM) and Delta Like Canonical Notch Ligand 4 (DLL4)) had a statistically significant association with T2D in univariate models. However, following adjustment for group, body mass index (BMI) and age, only ADIPOQ remained statistically significant. In Firth penalised logistic regression adjusted for PMOS status, age and BMI, each 1 SD higher ADIPOQ was associated with lower odds of incident T2D (OR 0.12; 95% CI 0.04–0.31); the association persisted when events were restricted to a common 10-year follow-up horizon, after adjustment for baseline fasting glucose, and after excluding women with baseline fasting glucose ≥ 7.0 mmol/L. Adding ADIPOQ to PMOS status, age and BMI increased the bootstrap optimism-corrected AUC from 0.74 to 0.87. In an independent experimental cohort (PMOS, n = 11; controls, n = 9, with SOMAscan data), ADIPOQ, neural cell adhesion molecule L1-like protein (CHL1), mast/stem cell growth factor receptor-Kit (KIT), chordin-like protein 1 (CHRDL1) and neural cell adhesion molecule L1 (L1CAM) were measured at 0, 180 and 300 min of 5 h saline and Intralipid infusions and analysed using linear mixed-effects models. Relative to saline, Intralipid lowered L1CAM, CHL1 and KIT at 180 min (differences in change from baseline −0.33, −0.30 and −0.25 log2 units; FDR-adjusted p ≤ 0.029), with no evidence that responses differed between women with PMOS and controls, and no lipid-specific change in ADIPOQ was detected; only the L1CAM response persisted after excluding turbid or haemolysed samples. Lower adiponectin was the only protein independently associated with incident T2D, whereas L1CAM, and less robustly CHL1 and KIT, responded to acute lipid exposure. The small number of events, differential outcome ascertainment between groups, absence of external validation and the exploratory experimental cohort preclude claims of clinical prediction. These findings support further evaluation of prognostic and stress-responsive protein phenotypes in larger, independently validated cohorts.

Verified
Journal Article
Open access
PDF file
EBEdwina Brennan
Edwina Brennan
AMAbu Saleh Md Moin
Abu Saleh Md Moin
Thozhukat  Sathyapalan Thozhukat Sathyapalan
Thozhukat Sathyapalan
LDLaura Dempsey
Laura Dempsey
SAStephen L Atkin
Stephen L Atkin
ABAlexandra E. Butler
Alexandra E. Butler
Hypoglycemia is associated with cardiovascular events reflected by platelet abnormalities. We hypothesized that sequential endothelial changes may occur during hypoglycemia that may enhance cardiovascular risk. In type 2 diabetes (T2D) (n = 23) and controls (n = 23), blood SOMAscan proteomic analysis of endothelial proteins at baseline, insulin-induced hypoglycemia and post hypoglycemia to 24 h were examined using repeated-measures linear mixed modeling with a prospective parallel study design. Most endothelial proteins that changed over time did not differ between groups. Baseline levels of P-selectin, plasminogen activator inhibitor-1 (PAI-1; serpine-1), E-selectin and angiopoietin-1 (ANGPT1) were significantly higher, whilst cadherin-5 was lower in T2D. Several proteins exhibited changes versus baseline in both T2D and controls. Under hypoglycemia, decreases in cadherin-5 and soluble angiopoietin-1 receptor (sTie-2) were observed, with increased P-selectin, intercellular adhesion molecule-3 (ICAM3), ANGPT1 and PAI-1. Post hypoglycemia, decreased cadherin-5 and ICAM5 were observed at 2 h and PAI-1 at 4 h, as well as increases in P-selectin at 30 min, 1 h and 24 h and ICAM3 at 24 h. Post hypoglycemia, E-selectin, P-selectin and ICAM3 were significantly lower in T2D patients at 2 h, while PAI-1 was significantly lower at 4 h and ICAM3 was significantly lower at 24 h. Baseline endothelial proteins differed between T2D and controls, which may suggest local endothelial inflammatory activation leading to a pro-thrombotic, destabilized vascular phenotype characteristic of diabetic vasculopathy. Hypoglycemia may exacerbate this towards a pro-adhesive and pro-thrombotic phenotype, worsening endothelial dysfunction.

17 May 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMariam Murad
Mariam Murad
PWPearl Wasif
Pearl Wasif
LDLaura Dempsey
Laura Dempsey
Roshan DeenRoshan Deen
Roshan Deen
ABAlexandra E. Butler
Alexandra E. Butler
SAStephen L Atkin
Stephen L Atkin
Objective: Sporopollenin exine capsules (SpECs) have been used to encapsulate active pharmaceutical agents for oral drug delivery. This study investigated whether fragrance encapsulated within SpECs prolonged perceived fragrance intensity compared with fragrance oil alone. Methods: A double-blind, placebo-controlled, randomized pilot study was conducted (clinical trial number: NCT07383337); ten healthy female participants (mean age 35.4 ± 5.6 years) received fragrance with SpEC-encapsulated fragrance (SpECs) on one wrist and fragrance alone (control) on the contralateral wrist. The fragrance intensity was assessed using a visual analogue scale (0–10) by both the participants and an independent blinded reviewer at baseline and after 2, 4 and 8 h. Paired Wilcoxon signed-rank tests and linear mixed-effects models were used for analysis. In vitro cytotoxicity was assessed using an ATP viability assay in human bronchial epithelial (BEAS-2B) cells exposed to SpECs or raw Lycopodium clavatum spores. Results: There were no significant differences between the formulations at baseline. From 2 h onward, SpECs was associated with significantly a higher fragrance intensity compared with the control for both participant-rated (p = 0.03 at 2 and 4 h; p = 0.005 at 8 h) and reviewer-rated assessments (p = 0.02 at 2 h; p = 0.01 at 4 h; and p = 0.008 at 8 h). Mixed-model analyses suggested a greater decline in intensity for control at 8 h for reviewer-rated assessments. In vitro, raw spores significantly reduced cell viability (as an indicator of potential allergenicity), whereas SpECs did not differ from control. Conclusions: Fragrance encapsulation within SpECs significantly prolongs measured fragrance intensity with no evidence of cytotoxicity. These findings support the potential of SpECs as a safe and effective sustained-release platform for topical fragrance formulations.